On October 20, 2023, a novel extended-release siRNA targeting KRASG12D/V (G12D/V) mutations (Loder) in combination with standard chemotherapy was reported at the ESMO Congress.

Qualigen Therapeutics reports the initial dosage in the Phase 1a QN-302 Clinical Study for Advanced or Metastatic Solid Tumors has been administered to the first patient.

Bruton's Tyrosine Kinase (BTK) inhibitors present a promising treatment for B-cell malignancies. Over the past decade, numerous clinical trials involving BTK inhibitors with anticancer potential have commenced, signaling a bright future for BTK inhibitors.

This article summarized the latest R&D progress of Rimonabant, the Mechanism of Action for Rimonabant, and the drug target R&D trends for Rimonabant.

On 23 Oct 2023, the results from a phase II trial of endostar in patients with locally advanced squamous cell carcinoma of esophagus were reported at the ESMO Congress.

The FDA greenlights Lilly's Zepbound™ (tirzepatide) - a potent, new choice for managing persistent weight issues, including obesity or overweight cases with health issues connected to weight.

BRD4 inhibitors, developed using computer-assisted drug design, are viewed as potential therapies for various diseases due to BRD4's involvement in gene expression, chromatin remodeling, cell cycle, and cancer.

This article summarized the latest R&D progress of Rivastigmine Tartrate, the Mechanism of Action for Rivastigmine Tartrate, and the drug target R&D trends for Rivastigmine Tartrate.

On October 20, 2023, “Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts) ”was reported at the ESMO Congress.

Amgen has revealed fresh information from the Phase 2 trial of dazodalibep, an experimental drug aimed to treat Sjögren's.

BRAF mutation is one of the significant therapeutic targets for various solid tumors, with BRAF inhibitors representing a major form of targeted combination therapy for BRAF mutation-positive solid tumors.

This article summarized the latest R&D progress of Sacituzumab govitecan-hziy, the Mechanism of Action for Sacituzumab govitecan-hziy, and the drug target R&D trends for Sacituzumab govitecan-hziy.